BioNTech tests new weapon against tough cancers

NCT ID NCT06150183

Ongoing Disease control Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

Summary

This is the first study in people to test the safety of a new cancer drug called BNT314. It involves 41 adults with advanced solid tumors that have progressed after standard treatments. The main goal is to find the highest dose that is safe and manageable, while also looking for early signs that the drug might help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

CHU de Liège

Liège, 4000, Belgium
Carolina BioOncology Institute, LLC

Huntersville, North Carolina, 28078, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Clinica Universidad de Navarra

Pamplona, 31008, Spain
GZA Ziekenhuizen

Antwerp, 2018, Belgium
Hospital Fund. Jiménez Dia

Madrid, 28040, Spain
Hospital HM Univ. Sanchinarro, Ensayos START

Madrid, 28050, Spain
Hospital Quironsalud Barcelona (NEXT Barcelona)

Barcelona, 08023, Spain
National Cancer Center Hospital East

Kashiwanoha, 277-8577, Japan
Northern Centre for Cancer Care

Newcastle, NE7 7DN, United Kingdom
Rigshospitalet

Copenhagen, DK-2100, Denmark
Royal Marsden Hospital - London

London, SW36JJ, United Kingdom
START Midwest

Grand Rapids, Michigan, 49546, United States
The Christie Hospital

Manchester, M20 4BX, United Kingdom

Conditions

Explore the condition pages connected to this study.

ADVANCED MALIGNANT SOLID TUMOR